Pulmonary fibrosis in response to environmental cues and molecular targets involved in its pathogenesis

Journal of Toxicologic Pathology

Volumn 24, Issue 1, 2011, Pages 9-24

  Yoshida, Toshinori ^a   Ohnuma, Aya ^a   Horiuchi, Haruka ^a   Harada, Takanori ^a  

^a INSTITUTE OF ENVIRONMENTAL TOXICOLOGY   (Japan)

Author keywords

Beryllium; Chemokine receptor; DDAC; Nylon fock; Regulatory T cell; TGF

Indexed keywords

BERYLLIUM; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 4; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR7; DIDECYLDIMETHYLAMMONIUM CHLORIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 4; MONOCYTE CHEMOTACTIC PROTEIN 5; NYLON; OSTEOGENIC PROTEIN 1; PAINT; POLYVINYLCHLORIDE; TRANSFORMING GROWTH FACTOR BETA;

CELL MIGRATION; ENVIRONMENTAL EXPOSURE; FIBROGENESIS; HUMAN; LUNG FIBROSIS; LYMPHOCYTE FUNCTION; MOLECULAR PATHOLOGY; NONHUMAN; OCCUPATIONAL EXPOSURE; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION;

EID: 79955411313     PISSN: 09149198     EISSN: None     Source Type: Journal    
DOI: 10.1293/tox.24.9     Document Type: Review

References (158)

1. Greaves P. Respiratory tract. In: Histopathology of Preclinical Toxicity Studies: Interpretation and Relevance in Drug Safety Evaluation, Third Edition. Elsevier Inc., Oxford, UK. 215-269. 2007. [Medline] [CrossRef]
2. King Jr TE. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am J Respir Crit Care Med. 172: 268-279. 2005. [Medline] [CrossRef]
3. American Thoracic Society European Respiratory Society American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classifcation of the Idiopathic Interstitial Pneumonias. (This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001). Am J Respir Crit Care Med. 165: 277-304. 2002. [Medline] [CrossRef]
4. Maher TM, Wells AU, and Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J. 30: 835-839. 2007. [Medline] [CrossRef]
5. Visscher DW, and Myers JL. Histologic spectrum of id-iopathic interstitial pneumonias. Proc Am Thorac Soc. 3: 322-329. 2006. [Medline] [CrossRef]
6. Taskar VS, and Coultas DB. Is idiopathic pulmonary f-brosis an environmental disease? Proc Am Thorac Soc. 3: 293-298. 2006. [Medline] [CrossRef]
7. Camus P, Fanton A, Bonniaud P, Camus C, and Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration. 71: 301-326. 2004. [Medline] [CrossRef]
8. Kelleher P, Pacheco K, and Newman LS. Inorganic dust pneumonias: the metal-related parenchymal disorders. Environ Health Perspect. 108(Suppl 4): 685-696. 2000. [Medline] [CrossRef]
9. Cooper RG, and Harrison AP. The uses and adverse effects of beryllium on health. Indian J Occup Environ Med. 13: 65-76. 2009. [Medline] [CrossRef]
10. + T cells in patients with chronic beryllium disease. J Clin Invest. 110: 1473-1482. 2002. [Medline] [CrossRef]
11. Cummings KJ, Stefaniak AB, Virji MA, and Kreiss K. A reconsideration of acute beryllium disease. Environ Health Perspect. 117: 1250-1256. 2009. [Medline] [CrossRef]
12. + T cells is dependent on a single amino acid residue of the MHC class II b-chain. J Immunol. 175: 7029-7037. 2005. [Medline] [CrossRef]
13. Fontenot AP, and Maier LA. Genetic susceptibility and immune-mediated destruction in beryllium-induced disease. Trends Immunol. 26: 543-549. 2005. [Medline] [CrossRef]
14. Dai S, Murphy GA, Crawford F, Mack DG, Falta MT, Mar-rack P, Kappler J W, and Fontenot A P. Crystal structure of HLA-DP2 and implications for chronic beryllium disease. Proc Natl Acad Sci USA. 107: 7425-7430. 2010. [Medline] [CrossRef]
15. Tarantino-Hutchison LM, Sorrentino C, Nadas A, Zhu Y, Rubin EM, Tinkle SS, Weston A, and Gordon T. Genetic determinants of sensitivity to beryllium in mice. J Immu-notoxicol. 6: 130-135. 2009. [Medline] [CrossRef]
16. Newman LS, Lloyd J, and Daniloff E. The natural history of beryllium sensitization and chronic beryllium disease. Environ Health Perspect. 104(Suppl 5): 937-943. 1996. [Medline] [CrossRef]
17. Nikula KJ, Swafford DS, Hoover MD, Tohulka MD, and Finch GL. Chronic granulomatous pneumonia and lympho-cytic responses induced by inhaled beryllium metal in A/J and C3H/HeJ mice. Toxicol Pathol. 25: 2-12. 1997. [Medline] [CrossRef]
18. Tinkle SS, Kittle LA, Schumacher BA, and Newman LS. Beryllium induces IL-2 and IFN-g in berylliosis. J Immunol. 158: 518-526. 1997. [Medline] [CrossRef]
19. Sawyer RT, Fontenot AP, Barnes TA, Parsons CE, Tooker BC, Maier LA, Gillespie MM, Gottschall EB, Silveira L, Hagman J, and Newman LS. Beryllium-induced TNF-a production is transcription-dependent in chronic beryllium disease. Am J Respir Cell Mol Biol. 36: 191-200. 2007. [Medline] [CrossRef]
20. Salehi F, Zayed J, Audusseau S, Muller C, Truchon G, Pla-mondon P, L'espérance G, Chevalier G, and Mazer B. Im-munological responses in C3H/HeJ mice following nose-only inhalation exposure to different sizes of beryllium metal particles. J Appl Toxicol. 29: 61-68. 2009. [Medline] [CrossRef]
21. + T cells in chronic beryllium disease. J Immunol. 180: 2704-2712. 2008. [Medline] [CrossRef]
22. Dobis DR, Sawyer RT, Gillespie MM, Huang J, Newman LS, Maier LA, and Day BJ. Modulation of lymphocyte proliferation by antioxidants in chronic beryllium disease. Am J Respir Crit Care Med. 177: 1002-1011. 2008. [Medline] [CrossRef]
23. Comhair SA, Lewis MJ, Bhathena PR, Hammel JP, and Er-zurum SC. Increased glutathione and glutathione peroxi-dase in lungs of individuals with chronic beryllium disease. Am J Respir Crit Care Med. 159: 1824-1829. 1999. [Medline] [CrossRef]
24. Kokturk N, Sabag M, Stark M, Grief J, and Fireman E. High extracellular induced sputum heme oxygenase-1 in sarcoid-osis and chronic beryllium disease. Eur J Clin Invest. 39: 584-590. 2009. [Medline] [CrossRef]
25. Inoue Y, King Jr TE, Tinkle SS, Dockstader K, and Newman LS. Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorders. Am J Pathol. 149: 2037-2054. 1996. [Medline] [CrossRef]
26. Lehnert NM, Gary RK, Marrone BL, and Lehnert BE. Inhibition of normal human lung fibroblast growth by beryllium. Toxicology. 160: 119-127. 2001. [Medline] [CrossRef]
27. Coates SS, Lehnert BE, Sharma S, Kindell SM, and Gary RK. Beryllium induces premature senescence in human fibroblasts. J Pharmacol Exp Ther. 322: 70-79. 2007. [Medline] [CrossRef]
28. Keshava N, Zhou G, Spruill M, Ensell M, and Ong TM. Carcinogenic potential and genomic instability of beryllium sulfate in BALB/c-3T3 cells. Mol Cell Biochem. 222: 69-76. 2001. [Medline] [CrossRef]
29. Jonth AC, Silveira L, Fingerlin TE, Sato H, Luby JC, Welsh KI, Rose CS, Newman LS, du Bois RM, and Maier LA. ACCESS Group. TGF-β1 variants in chronic beryllium disease and sarcoidosis. J Immunol. 179: 4255-4262. 2007. [Medline] [CrossRef]
30. Kern DG, Kuhn 3rd C, Ely EW, Pransky GS, Mello CJ, Frai-re AE, and Müller J. Flock worker's lung: broadening the spectrum of clinicopathology, narrowing the spectrum of suspected etiologies. Chest. 117: 251-259. 2000. [Medline] [CrossRef]
31. Eschenbacher WL, Kreiss K, Lougheed MD, Pransky GS, Day B, and Castellan RM. Nylon fock-associated interstitial lung disease. Am J Respir Crit Care Med. 159: 2003- 2008. 1999. [Medline] [CrossRef]
32. Boag AH, Colby TV, Fraire AE, Kuhn 3rd C, Roggli VL, Travis WD, and Vallyathan V. The pathology of interstitial lung disease in nylon fock workers. Am J Surg Pathol. 23: 1539-1545. 1999. [Medline] [CrossRef]
33. Warheit DB, Hart GA, Hesterberg TW, Collins JJ, Dyer WM, Swaen GM, Castranova V, Soiefer AI, and Kennedy Jr GL. Potential pulmonary effects of man-made organic fber (MMOF) dusts. Crit Rev Toxicol. 31: 697-736. 2001. [Medline] [CrossRef]
34. Porter DW, Castranova V, Robinson VA, Hubbs AF, Mercer RR, Scabilloni J, Goldsmith T, Schwegler-Berry D, Battelli L, Washko R, Burkhart J, Piacitelli C, Whitmer M, and Jones W. Acute inflammatory reaction in rats after intratra-cheal instillation of material collected from a nylon focking plant. J Toxicol Environ Health A. 57: 25-45. 1999. [Medline] [CrossRef]
35. Warheit DB, Webb TR, Reed KL, Hansen JF, and Kennedy Jr GL. Four-week inhalation toxicity study in rats with nylon respirable fbers: rapid lung clearance. Toxicology. 192: 189-210. 2003. [Medline] [CrossRef]
36. Ghio AJ, Funkhouser W, Pugh CB, Winters S, Stonehuerner JG, Mahar AM, and Roggli VL. Pulmonary fibrosis and ferruginous bodies associated with exposure to synthetic fbers. Toxicol Pathol. 34: 723-729. 2006. [Medline] [CrossRef]
37. Moya C, Antó JM, and Taylor AJ. Outbreak of organizing pneumonia in textile printing sprayers. Collaborative Group for the Study of Toxicity in Textile Aerographic Factories. Lancet. 344: 498-502. 1994. [Medline] [CrossRef]
38. Romero S, Hernández L, Gil J, Aranda I, Martín C, and Sanchez-Payá J. Organizing pneumonia in textile printing workers: a clinical description. Eur Respir J. 11: 265-271. 1998. [Medline] [CrossRef]
39. Solé A, Cordero PJ, Morales P, Martínez ME, Vera F, and Moya C. Epidemic outbreak of interstitial lung disease in aerographics textile workers-the "Ardystil syndrome": a frst year follow up. Thorax. 51: 94-95. 1996. [Medline] [CrossRef]
40. Hoet PH, Gilissen LP, Leyva M, and Nemery B. In vitro cytotoxicity of textile paint components linked to the "Ar-dystil syndrome". Toxicol Sci. 52: 209-216. 1999. [Medline] [CrossRef]
41. Clottens FL, Verbeken EK, Demedts M, and Nemery B. Pulmonary toxicity of components of textile paint linked to the Ardystil syndrome: intratracheal administration in hamsters. Occup Environ Med. 54: 376-387. 1997. [Medline] [CrossRef]
42. Hoet PH, Gilissen L, and Nemery B. Polyanions protect against the in vitro pulmonary toxicity of polycationic paint components associated with the Ardystil syndrome. Toxicol Appl Pharmacol. 175: 184-190. 2001. [Medline] [CrossRef]
43. Soutar CA, Copland LH, Thornley PE, Hurley JF, Ottery J,Adams WG, and Bennett B. Epidemiological study of respiratory disease in workers exposed to polyvinylchloride dust. Thorax. 35: 644-652. 1980. [Medline] [CrossRef]
44. Lilis R. Review of pulmonary effects of poly(vinyl chloride) and vinyl chloride exposure. Environ Health Perspect. 41: 167-169. 1981. [Medline] [CrossRef]
45. Cordasco EM, Demeter SL, Kerkay J, Van Ordstrand HS, Lucas EV, Chen T, and Golish JA. Pulmonary manifestations of vinyl and polyvinyl chloride (interstitial lung disease). Newer aspects. Chest. 78: 828-834. 1980. [Medline] [CrossRef]
46. Arnaud A, Pommier de Santi PP, Garbe L, Payan H, and Charpin J. Polyvinyl chloride pneumoconiosis. Thorax. 33: 19-25. 1978. [Medline] [CrossRef]
47. Antti-Poika M, Nordman H, Nickels J, Keskinen H, and Vil-janen A. Lung disease after exposure to polyvinyl chloride dust. Thorax. 41: 566-567. 1986. [Medline] [CrossRef]
48. White NW, and Ehrlich RI. Regression of polyvinylchloride polymer pneumoconiosis. Thorax. 52: 748-749. 1997. [Medline] [CrossRef]
49. Groth DH, Lynch DW, Moorman WJ, Stettler LE, Lewis TR, Wagner WD, and Kommineni C. Pneumoconiosis in animals exposed to poly(vinyl chloride) dust. Environ Health Perspect. 41: 73-81. 1981. [Medline] [CrossRef]
50. Xu H, Dinsdale D, Nemery B, and Hoet PH. Role of residual additives in the cytotoxicity and cytokine release caused by polyvinyl chloride particles in pulmonary cell cultures. Toxicol Sci. 72: 92-102. 2003. [Medline] [CrossRef]
51. Xu H, Verbeken E, Vanhooren HM, Nemery B, and Hoet PH. Pulmonary toxicity of polyvinyl chloride particles after a single intratracheal instillation in rats. Time course and comparison with silica. Toxicol Appl Pharmacol. 194: 111-121. 2004. [Medline] [CrossRef]
52. Xu H, Vanhooren HM, Verbeken E, Yu L, Lin Y, Nemery B, and Hoet PH. Pulmonary toxicity of polyvinyl chloride particles after repeated intratracheal instillations in rats. Elevated CD4/CD8 lymphocyte ratio in bronchoalveolar lavage. Toxicol Appl Pharmacol. 194: 122-131. 2004. [Medline] [CrossRef]
53. Gannon PF, Burge PS, and Benfeld GF. Occupational asthma due to polyethylene shrink wrapping (paper wrapper's asthma). Thorax. 47: 759. 1992. [Medline] [CrossRef]
54. Tuomainen A, Stark H, Seuri M, Hirvonen MR, Linnainmaa M, Sieppi A, and Tukiainen H. Experimental PVC material challenge in subjects with occupational PVC exposure. Environ Health Perspect. 114: 1409-1413. 2006. [Medline] [CrossRef]
55. Skaliy P, Thompson TA, Gorman GW, Morris GK, McEach-ern HV, and Mackel DC. Laboratory studies of disinfectants against Legionella pneumophila. Appl Environ Microbiol. 40: 697-700. 1980. [Medline] [CrossRef]
56. Kanazawa A, Ikeda T, and Endo T. Synthesis and antimicrobial activity of dimethyl- and trimethyl-substituted phos-phonium salts with alkyl chains of various lengths. Antimi-crob Agents Chemother. 38: 945-952. 1994. [Medline] [CrossRef]
57. Dickey P. Guidelines for selecting wood preservatives. For the San Francisco Department of the Environment. Sep- tember 9, 2003. [The guidelines are available at http://www.sfenvironment.org/downloads/library/preservatives.pdf]. [Medline] [CrossRef]
58. Walsh SE, Maillard JY, Russell AD, Catrenich CE, Char-bonneau DL, and Bartolo RG. Activity and mechanisms of action of selected biocidal agents on Gram-positive and -negative bacteria. J Appl Microbiol. 94: 240-247. 2003. [Medline] [CrossRef]
59. United States Environmental Protection Agency. Reregis-tration eligibility decision for aliphatic alkyl quaternaries (DDAC). August, 2006. [The guidelines are available at http://www.epa.gov/oppsrrd1/REDs/ddac_red.pdf]. [Medline] [CrossRef]
60. Yoshimatsu T, and Hiyama K. Mechanism of the action of didecyldimethylammonium chloride (DDAC) against Esch-erichia coil and morphological changes of the cells. Biocontrol Sci. 12: 93-99. 2007. [Medline] [CrossRef]
61. Ioannou CJ, Hanlon GW, and Denyer SP. Action of disinfectant quaternary ammonium compounds against Staphy-lococcus aureus. Antimicrob Agents Chemother. 51: 296- 306. 2007. [Medline] [CrossRef]
62. Dejobert Y, Martin P, Piette F, Thomas P, and Bergoend H. Contact dermatitis from didecyldimethylammonium chloride and bis-(aminopropyl)-lauryl amine in a detergent-disinfectant used in hospital. Contact Dermatitis. 37: 95-96. 1997. [Medline] [CrossRef]
63. Bernstein JA, Stauder T, Bernstein DI, and Bernstein IL. A combined respiratory and cutaneous hypersensitivity syndrome induced by work exposure to quaternary amines. J Allergy Clin Immunol. 94: 257-259. 1994. [Medline] [CrossRef]
64. Burge PS, and Richardson MN. Occupational asthma due to indirect exposure to lauryl dimethyl benzyl ammonium chloride used in a foor cleaner. Thorax. 49: 842-843. 1994. [Medline] [CrossRef]
65. Purohit A, Kopferschmitt-Kubler MC, Moreau C, Popin E, Blaumeiser M, and Pauli G. Quaternary ammonium compounds and occupational asthma. Int Arch Occup Environ Health. 73: 423-427. 2000. [Medline] [CrossRef]
66. Vincent G, Kopferschmitt-Kubler MC, Mirabel P, Pauli G, and Millet M. Sampling and analysis of quaternary ammonium compounds (QACs) traces in indoor atmosphere. Environ Monit Assess. 133: 25-30. 2007. [Medline] [CrossRef]
67. Shirai J, Kanno T, Inoue T, Mitsubayashi S, and Seki R. Effects of quaternary ammonium compounds with 0.1% sodium hydroxide on swine vesicular disease virus. J Vet Med Sci. 59: 323-328. 1997. [Medline] [CrossRef]
68. Shirai J, Kanno T, Tsuchiya Y, Mitsubayashi S, and Seki R. Effects of chlorine, iodine, and quaternary ammonium compound disinfectants on several exotic disease viruses. J Vet Med Sci. 62: 85-92. 2000. [Medline] [CrossRef]
69. Ohnuma A, Yoshida T, Tajima H, Fukuyama T, Hayashi K, Yamaguchi S, Ohtsuka R, Sasaki J, Fukumori J, Tomita M, Kojima S, Takahashi N, Takeuchi Y, Kuwahara M, Takeda M, Kosaka T, Nakashima N, and Harada T. Didecyldi-methylammonium chloride induces pulmonary inflammation and fibrosis in mice. Exp Toxicol Pathol. 62: 643-651. 2010. [Medline] [CrossRef]
70. BIBRA Toxicity Profle: Didecyldimethylammonium Chloride. BIBRA International Ltd., Carshalton, UK, 1990. [Medline] [CrossRef]
71. Xue Y, Hieda Y, Saito Y, Nomura T, Fujihara J, Takayama K, Kimura K, and Takeshita H. Distribution and disposition of benzalkonium chloride following various routes of administration in rats. Toxicol Lett. 148: 113-123. 2004. [Medline] [CrossRef]
72. Swiercz R, Hałatek T, Wasowicz W, Kur B, Grzelińska Z, and Majcherek W. Pulmonary irritation after inhalation exposure to benzalkonium chloride in rats. Int J Occup Med Environ Health. 21: 157-163. 2008. [Medline] [CrossRef]
73. Tokuda A, Itakura M, Onai N, Kimura H, Kuriyama T, and Matsushima K. Pivotal role of CCR1-positive leukocytes in bleomycin-induced lung fibrosis in mice. J Immunol. 164: 2745-2751. 2001. [Medline] [CrossRef]
74. Moore BB, Paine 3rd R, Christensen PJ, Moore TA, Sitter-ding S, Ngan R, Wilke CA, Kuziel WA, and Toews GB. Protection from pulmonary fibrosis in the absence of CCR2 signaling. J Immunol. 167: 4368-4377. 2001. [Medline] [CrossRef]
75. Yara S, Kawakami K, Kudeken N, Tohyama M, Teruya K, Chinen T, Awaya A, and Saito A. FTS reduces bleomycin-induced cytokine and chemokine production and inhibits pulmonary fibrosis in mice. Clin Exp Immunol. 124: 77-85. 2001. [Medline] [CrossRef]
76. Huaux F, Gharaee-Kermani M, Liu T, Morel V, McGarry B, Ullenbruch M, Kunkel SL, Wang J, Xing Z, and Phan SH. Role of Eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis. Am J Pathol. 167: 1485-1496. 2005. [Medline] [CrossRef]
77. Ishida Y, Kimura A, Kondo T, Hayashi T, Ueno M, Takaku-ra N, Matsushima K, and Mukaida N. Essential roles of the CC chemokine ligand 3-CC chemokine receptor 5 axis in bleomycin-induced pulmonary fibrosis through regulation of macrophage and fibrocyte infltration. Am J Pathol. 170: 843-854. 2007. [Medline] [CrossRef]
78. Luzina IG, Todd NW, Iacono AT, and Atamas SP. Roles of T lymphocytes in pulmonary fibrosis. J Leukoc Biol. 83: 237-244. 2008. [Medline] [CrossRef]
79. Hasegawa M, Sato S, and Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1a (MIP-1a) and MIP-1b) in patients with systemic sclerosis: MCP-1 and MIP-1a may be involved in the development of pulmonary fibrosis. Clin Exp Immunol. 117: 159-165. 1999. [Medline] [CrossRef]
80. Smith RE, Strieter RM, Zhang K, Phan SH, Standiford TJ, Lukacs NW, and Kunkel SL. A role for C-C chemo-kines in fibrotic lung disease. J Leukoc Biol. 57: 782-787. 1995. [Medline] [CrossRef]
81. Emad A, and Emad V. Elevated levels of MCP-1, MIP-a and MIP-1b in the bronchoalveolar lavage (BAL) fuid of patients with mustard gas-induced pulmonary fibrosis. Toxicology. 240: 60-69. 2007. [Medline] [CrossRef]
82. Shinoda H, Tasaka S, Fujishima S, Yamasawa W, Miyamoto K, Nakano Y, Kamata H, Hasegawa N, and Ishizaka A. Elevated CC chemokine level in bronchoalveolar lavage fuid is predictive of a poor outcome of idiopathic pulmonary fibro-sis. Respiration. 78: 285-292. 2009. [Medline] [CrossRef]
83. Deshmane SL, Kremlev S, Amini S, and Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 29: 313-326. 2009. [Medline] [CrossRef]
84. Gharaee-Kermani M, Denholm EM, and Phan SH. Co-stimulation of fibroblast collagen and transforming growth factor b1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem. 271: 17779-17784. 1996. [Medline] [CrossRef]
85. Yamamoto T, Eckes B, Mauch C, Hartmann K, and Krieg T. Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1a loop. J Immunol. 164: 6174-6179. 2000. [Medline] [CrossRef]
86. Agostini C, and Gurrieri C. Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis. Proc Am Thorac Soc. 3: 357-363. 2006. [Medline] [CrossRef]
87. Gharaee-Kermani M, McCullumsmith RE, Charo IF, Kun-kel SL, and Phan SH. CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis. Cytokine. 24: 266-276. 2003. [Medline] [CrossRef]
88. Okuma T, Terasaki Y, Kaikita K, Kobayashi H, Kuziel WA, Kawasuji M, and Takeya M. C-C chemokine receptor 2 (CCR2) deficiency improves bleomycin-induced pulmonary fibrosis by attenuation of both macrophage infltration and production of macrophage-derived matrix metallopro-teinases. J Pathol. 204: 594-604. 2004. [Medline] [CrossRef]
89. Moore BB, Peters-Golden M, Christensen PJ, Lama V, Kuz-iel WA, Paine 3rd R, and Toews GB. Alveolar epithelial cell inhibition of fibroblast proliferation is regulated by MCP-1/ CCR2 and mediated by PGE2. Am J Physiol Lung Cell Mol Physiol. 284: L342-L349. 2003. [Medline] [CrossRef]
90. Reichel CA, Khandoga A, Anders HJ, Schlöndorff D, Luck-ow B, and Krombach F. Chemokine receptors Ccr1, Ccr2, and Ccr5 mediate neutrophil migration to postischemic tissue. J Leukoc Biol. 79: 114-122. 2006. [Medline] [CrossRef]
91. Moore BB, Kolodsick JE, Thannickal VJ, Cooke K, Moore TA, Hogaboam C, Wilke CA, and Toews GB. CCR2-me-diated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol. 166: 675-684. 2005. [Medline] [CrossRef]
92. Saraf MN, Garcia-Zepeda EA, MacLean JA, Charo IF, and Luster AD. Murine monocyte chemoattractant protein (MCP)-5: a novel CC chemokine that is a structural and functional homologue of human MCP-1. J Exp Med. 185: 99-109. 1997. [Medline] [CrossRef]
93. Moore BB, Murray L, Das A, Wilke CA, Herrygers AB, and Toews GB. The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am J Respir Cell Mol Biol. 35: 175-181. 2006. [Medline] [CrossRef]
94. Tsou CL, Peters W, Si Y, Slaymaker S, Aslanian AM, Weis-berg SP, Mack M, and Charo IF. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J Clin Invest. 117: 902-909. 2007. [Medline] [CrossRef]
95. Yoshida T, and Tuder RM. Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease. Physiol Rev. 87: 1047-1082. 2007. [Medline] [CrossRef]
96. Shang X, Qiu B, Frait KA, Hu JS, Sonstein J, Curtis JL, Lu B, Gerard C, and Chensue SW. Chemokine receptor 1 knockout abrogates natural killer cell recruitment and impairs type-1 cytokines in lymphoid tissue during pulmonary granuloma formation. Am J Pathol. 157: 2055-2063. 2000. [Medline] [CrossRef]
97. -/- mice during chronic fungal allergic airway disease. J Immunol. 165: 1564-1572. 2000. [Medline] [CrossRef]
98. Horuk R. Chemokine receptors. Cytokine Growth Factor Rev. 12: 313-335. 2001. [Medline] [CrossRef]
99. Belperio JA, Dy M, Murray L, Burdick MD, Xue YY, Stri-eter RM, and Keane MP. The role of the Th2 CC chemo-kine ligand CCL17 in pulmonary fibrosis. J Immunol. 173: 4692-4698. 2004. [Medline] [CrossRef]
100. Trujillo G, O'Connor EC, Kunkel SL, and Hogaboam CM. A novel mechanism for CCR4 in the regulation of macro-phage activation in bleomycin-induced pulmonary fibrosis. Am J Pathol. 172: 1209-1221. 2008. [Medline] [CrossRef]
101. Misson P, van den Brûle S, Barbarin V, Lison D, and Huaux F. Markers of macrophage differentiation in experimental silicosis. J Leukoc Biol. 76: 926-932. 2004. [Medline] [CrossRef]
102. Ckless K, Lampert A, Reiss J, Kasahara D, Poynter ME, Irvin CG, Lundblad LK, Norton R, van der Vliet A, and Janssen-Heininger YM. Inhibition of arginase activity enhances inflammation in mice with allergic airway disease, in association with increases in protein S-nitrosylation and tyrosine nitration. J Immunol. 181: 4255-4264. 2008. [Medline] [CrossRef]
103. Liu T, Dhanasekaran SM, Jin H, Hu B, Tomlins SA, Ch-innaiyan AM, and Phan SH. FIZZ1 stimulation of myo-fibroblast differentiation. Am J Pathol. 164: 1315-1326. 2004. [Medline] [CrossRef]
104. Liu T, Hu B, Choi YY, Chung M, Ullenbruch M, Yu H, Lowe JB, and Phan SH. Notch1 signaling in FIZZ1 induction of myofibroblast differentiation. Am J Pathol. 174: 1745-1755. 2009. [Medline] [CrossRef]
105. Choi ES, Pierce EM, Jakubzick C, Carpenter KJ, Kunkel SL, Evanoff H, Martinez FJ, Flaherty KR, Moore BB, Toews GB, Colby TV, Kazerooni EA, Gross BH, Travis WD, and Hogaboam CM. Focal interstitial CC chemokine receptor 7 (CCR7) expression in idiopathic interstitial pneumonia. J Clin Pathol. 59: 28-39. 2006. [Medline] [CrossRef]
106. Pierce EM, Carpenter K, Jakubzick C, Kunkel SL, Evanoff H, Flaherty KR, Martinez FJ, Toews GB, and Hogaboam CM. Idiopathic pulmonary fibrosis fibroblasts migrate and proliferate to CC chemokine ligand 21. Eur Respir J. 29: 1082-1093. 2007. [Medline] [CrossRef]
107. -/- mice. Fibrogenesis Tissue Repair. 3: 18. 2010. [Medline] [CrossRef]
108. Sobiecka M, Kus J, Demkow U, Filewska M, Jozwik A, Radwan-Rohrenschef P, and Chorostowska-Wynimko J. Induced sputum in patients with interstitial lung disease: a non-invasive surrogate for certain parameters in bron-choalveolar lavage fuid. J Physiol Pharmacol. 59(Suppl 6): 645-657. 2008. [Medline] [CrossRef]
109. Feghali-Bostwick CA, Tsai CG, Valentine VG, Kantrow S, Stoner MW, Pilewski JM, Gadgil A, George MP, Gibson KF, Choi AM, Kaminski N, Zhang Y, and Duncan SR. Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis. J Immunol. 179: 2592-2599. 2007. [Medline] [CrossRef]
110. van Oosterhout AJ, and Bloksma N. Regulatory T-lympho-cytes in asthma. Eur Respir J. 26: 918-932. 2005. [Medline] [CrossRef]
111. Schubert LA, Jeffery E, Zhang Y, Ramsdell F, and Ziegler SF. Scurfn (FOXP3) acts as a repressor of transcription and regulates T cell activation. J Biol Chem. 276: 37672-37679. 2001. [Medline] [CrossRef]
112. Fontenot JD, Gavin MA, and Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 4: 330-336. 2003. [Medline] [CrossRef]
113. Hori S, Nomura T, and Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 299: 1057-1061. 2003. [Medline] [CrossRef]
114. + T regulatory cells. Nat Immunol. 4: 337-342. 2003. [Medline] [CrossRef]
115. + T cells differentiates effector from regulatory T cell subsets in the lung. J Immunol. 182: 7317-7324. 2009. [Medline] [CrossRef]
116. + regulatory T cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 179: 1121-1130. 2009. [Medline] [CrossRef]
117. Gilani SR, Vuga LJ, Lindell KO, Gibson KF, Xue J, Ka-minski N, Valentine VG, Lindsay EK, George MP, Steele C, and Duncan SR. CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS One. 5: e8959. 2010. [Medline] [CrossRef]
118. + regulatory T cells suppress early stages of granuloma formation but have little impact on sarcoidosis lesions. Am J Pathol. 174: 497-508. 2009. [Medline] [CrossRef]
119. Verrecchia F, and Mauviel A. Transforming growth factor-β and fibrosis. World J Gastroenterol. 13: 3056-3062. 2007. [Medline] [CrossRef]
120. Koli K, Myllärniemi M, Vuorinen K, Salmenkivi K, Ryynänen MJ, Kinnula VL, and Keski-Oja J. Bone morphogenetic protein-4 inhibitor gremlin is overexpressed in idiopathic pulmonary fibrosis. Am J Pathol. 169: 61-71. 2006. [Medline] [CrossRef]
121. Coker RK, Laurent GJ, Shahzeidi S, Lympany PA, du Bois RM, Jeffery PK, and McAnulty RJ. Transforming growth factors-b1, -b2, and -b3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis. Am J Pathol. 150: 981-991. 1997. [Medline] [CrossRef]
122. Eickelberg O, Köhler E, Reichenberger F, Bertschin S, Woodtli T, Erne P, Perruchoud AP, and Roth M. Extracellular matrix deposition by primary human lung fibroblasts in response to TGF-β1 and TGF-β3. Am J Physiol. 276: L814- L824. 1999. [Medline] [CrossRef]
123. Bobik A. Transforming growth factor-βs and vascular disorders. Arterioscler Thromb Vasc Biol. 26: 1712-1720. 2006. [Medline] [CrossRef]
124. Piek E, Heldin CH, and Ten Dijke P. Specificity, diversity, and regulation in TGF-β superfamily signaling. FASEB J. 13: 2105-2124. 1999. [Medline] [CrossRef]
125. Leask A, and Abraham DJ. TGF-β signaling and the fibrotic response. FASEB J. 18: 816-827. 2004. [Medline] [CrossRef]
126. Zhao J, Shi W, Wang YL, Chen H, Bringas Jr P, Datto MB, Frederick JP, Wang XF, and Warburton D. Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol. 282: L585-L593. 2002. [Medline] [CrossRef]
127. Bonniaud P, Kolb M, Galt T, Robertson J, Robbins C, Stamp-fi M, Lavery C, Margetts PJ, Roberts AB, and Gauldie J. Smad3 null mice develop airspace enlargement and are resistant to TGF-β-mediated pulmonary fibrosis. J Immunol. 173: 2099-2108. 2004[Medline] [CrossRef]
128. Zhang W, Ou J, Inagaki Y, Greenwel P, and Ramirez F. Synergistic cooperation between Sp1 and Smad3/Smad4 mediates transforming growth factor b1 stimulation of a2(I)-collagen (COL1A2) transcription. J Biol Chem. 275: 39237-39245. 2000. [Medline] [CrossRef]
129. Xu Y, Sengupta PK, Seto E, and Smith BD. Regulatory factor for X-box family proteins differentially interact with his-tone deacetylases to repress collagen a2(I) gene (COL1A2) expression. J Biol Chem. 281: 9260-9270. 2006. [Medline] [CrossRef]
130. Xu Y, Farmer SR, and Smith BD. Peroxisome proliferator-activated receptor g interacts with CIITA·RFX5 complex to repress type I collagen gene expression. J Biol Chem. 282: 26046-26056. 2007. [Medline] [CrossRef]
131. Lin X, Duan X, Liang YY, Su Y, Wrighton KH, Long J, Hu M, Davis CM, Wang J, Brunicardi FC, Shi Y, Chen YG, Meng A, and Feng XH. PPM1A functions as a Smad phos-phatase to terminate TGF-β signaling. Cell. 125: 915-928. 2006. [Medline] [CrossRef]
132. Bu S, Kapanadze B, Hsu T, and Trojanowska M. Opposite effects of dihydrosphingosine 1-phosphate and sphingosine 1-phosphate on transforming growth factor-β/Smad signaling are mediated through the PTEN/PPM1A-dependent pathway. J Biol Chem. 283: 19593-19602. 2008. [Medline] [CrossRef]
133. Xin C, Ren S, Kleuser B, Shabahang S, Eberhardt W, Rade-ke H, Schäfer-Korting M, Pfeilschifter J, and Huwiler A. Sphingosine 1-phosphate cross-activates the Smad signaling cascade and mimics transforming growth factor-β-induced cell responses. J Biol Chem. 279: 35255-35262. 2004. [Medline] [CrossRef]
134. Kono Y, Nishiuma T, Nishimura Y, Kotani Y, Okada T, Na-kamura S, and Yokoyama M. Sphingosine kinase 1 regulates differentiation of human and mouse lung fibroblasts mediated by TGF-β1. Am J Respir Cell Mol Biol. 37: 395-404. 2007. [Medline] [CrossRef]
135. Zhao J, Shi W, Chen H, and Warburton D. Smad7 and Smad6 differentially modulate transforming growth factor b-induced inhibition of embryonic lung morphogenesis. J Biol Chem. 275: 23992-23997. 2000. [Medline] [CrossRef]
136. Inoue Y, and Imamura T. Regulation of TGF-β family signaling by E3 ubiquitin ligases. Cancer Sci. 99: 2107-2112. 2008. [Medline] [CrossRef]
137. Zhang S, Fei T, Zhang L, Zhang R, Chen F, Ning Y, Han Y, Feng XH, Meng A, and Chen YG. Smad7 antagonizes transforming growth factor b signaling in the nucleus by interfering with functional Smad-DNA complex formation. Mol Cell Biol. 27: 4488-4499. 2007. [Medline] [CrossRef]
138. Venkatesan N, Pini L, and Ludwig MS. Changes in Smad expression and subcellular localization in bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 287: L1342-L1347. 2004. [Medline] [CrossRef]
139. Gonzalez AV, Le Bellego F, and Ludwig MS. Imbalance of receptor-regulated and inhibitory Smads in lung fibroblasts from bleomycin-exposed rats. Am J Respir Cell Mol Biol. 36: 206-212. 2007. [Medline] [CrossRef]
140. Nakao A, Fujii M, Matsumura R, Kumano K, Saito Y, Miya-zono K, and Iwamoto I. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest. 104: 5-11. 1999. [Medline] [CrossRef]
141. Wen FQ, Liu X, Kobayashi T, Abe S, Fang Q, Kohyama T, Ertl R, Terasaki Y, Manouilova L, and Rennard SI. Inter-feron-g inhibits transforming growth factor-β production in human airway epithelial cells by targeting Smads. Am J Respir Cell Mol Biol. 30: 816-822. 2004. [Medline] [CrossRef]
142. Shukla MN, Rose JL, Ray R, Lathrop KL, Ray A, and Ray P. Hepatocyte growth factor inhibits epithelial to myofibro-blast transition in lung cells via Smad7. Am J Respir Cell Mol Biol. 40: 643-653. 2009. [Medline] [CrossRef]
143. Csiszar A, Ahmad M, Smith KE, Labinskyy N, Gao Q, Kal-ey G, Edwards JG, Wolin MS, and Ungvari Z. Bone morphogenetic protein-2 induces proinflammatory endothelial phenotype. Am J Pathol. 168: 629-638. 2006. [Medline] [CrossRef]
144. Frank DB, Abtahi A, Yamaguchi DJ, Manning S, Shyr Y, Pozzi A, Baldwin HS, Johnson JE, and de Caestecker MP. Bone morphogenetic protein 4 promotes pulmonary vascular remodeling in hypoxic pulmonary hypertension. Circ Res. 97: 496-504. 2005. [Medline] [CrossRef]
145. Izumi N, Mizuguchi S, Inagaki Y, Saika S, Kawada N, Na-kajima Y, Inoue K, Suehiro S, Friedman SL, and Ikeda K. BMP-7 opposes TGF-β1-mediated collagen induction in mouse pulmonary myofibroblasts through Id2. Am J Physi- ol Lung Cell Mol Physiol. 290: L120-L126. 2006. [Medline] [CrossRef]
146. Kowanetz M, Valcourt U, Bergström R, Heldin CH, and Moustakas A. Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor b and bone morphogenetic protein. Mol Cell Biol. 24: 4241-4254. 2004. [Medline] [CrossRef]
147. Valcourt U, Kowanetz M, Niimi H, Heldin CH, and Mousta-kas A. TGF-β and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Biol Cell. 16: 1987-2002. 2005. [Medline] [CrossRef]
148. Myllärniemi M, Lindholm P, Ryynänen MJ, Kliment CR, Salmenkivi K, Keski-Oja J, Kinnula VL, Oury TD, and Koli K. Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis. Am J Respir Crit Care Med. 177: 321-329. 2008. [Medline] [CrossRef]
149. Murray LA, Hackett TL, Warner SM, Shaheen F, Argent-ieri RL, Dudas P, Farrell FX, and Knight DA. BMP-7 does not protect against bleomycin-induced lung or skin fibrosis. PLoS One. 3: e4039. 2008. [Medline] [CrossRef]
150. Pegorier S, Campbell GA, Kay AB, and Lloyd CM. Bone morphogenetic protein (BMP)-4 and BMP-7 regulate differentially transforming growth factor (TGF)-b1 in normal human lung fibroblasts (NHLF). Respir Res. 11: 85. 2010.[Medline] [CrossRef]
151. Koli K, Wempe F, Sterner-Kock A, Kantola A, Komor M, Hofmann WK, von Melchner H, and Keski-Oja J. Disruption of LTBP-4 function reduces TGF-β activation and enhances BMP-4 signaling in the lung. J Cell Biol. 167: 123- 133. 2004. [Medline] [CrossRef]
152. Costello CM, Cahill E, Martin F, Gaine S, and McLoughlin P. Role of gremlin in the lung: development and disease. Am J Respir Cell Mol Biol. 42: 517-523. 2010. [Medline] [CrossRef]
153. Wilson MS, and Wynn TA. Pulmonary fibrosis: pathogene-sis, etiology and regulation. Mucosal Immunol. 2: 103-121. 2009. [Medline] [CrossRef]
154. Gauldie J, Kolb M, and Sime PJ. A new direction in the pathogenesis of idiopathic pulmonary fibrosis? Respir Res. 3: 1. 2002. [Medline] [CrossRef]
155. Chua F, Gauldie J, and Laurent GJ. Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol. 33: 9-13. 2005. [Medline] [CrossRef]
156. Richeldi L. Chronic beryllium disease: a model for pulmonary sarcoidosis? Acta Biomed. 76(Suppl 2): 11-14. 2005. [Medline] [CrossRef]
157. Chen ES, and Moller DR. Expression profling in granu-lomatous lung disease. Proc Am Thorac Soc. 4: 101-107. 2007. [Medline] [CrossRef]
158. Gennaro V, Ceppi M, Crosignani P, and Montanaro F. Re-analysis of updated mortality among vinyl and polyvinyl chloride workers: confrmation of historical evidence and new fndings. BMC Public Health. 8: 21. 2008. [Medline] [CrossRef]